Review Papers Faster

 Quick Answer Copied

 Long Answer

Reported Quantitative Findings

The authors FACS-sorted CD133-positive U87 cells, grew them as tumorspheres in serum-free medium, and confirmed CD133/Nestin positivity with GFAP negativity. TaqMan RT-qPCR (normalized to RNU6B, 2^-DDCt method) showed miR-34a ~3.62-fold lower in U87 GSCs than parental U87 cells (P<0.01; three independent experiments) MicroRNA-34a Suppresses Cell Proliferation and Induces Apoptosis in U87 Glioma Stem Cells [2012]. FAM-conjugated oligo FACS showed 88.90% transfection efficiency, and mimics raised miR-34a ~8.36-fold above GSC blank controls 48 h post-transfection MicroRNA-34a Suppresses Cell Proliferation and Induces Apoptosis in U87 Glioma Stem Cells [2012]. Functional readouts: fewer secondary tumorspheres and soft-agar colonies, G1-phase cell-cycle arrest, reduced cyclin D1, c-myc, c-Met and Ki-67, increased Annexin V-positive apoptosis, and Western-blot shifts of Bcl-2/Bcl-w/Bcl-xL down and Bax up. Only threshold P-values (P<0.05, P<0.01) are reported; exact effect sizes, F-statistics and confidence intervals are absent.

Mechanistic Claims: Observation vs Interpretation

Observed: correlated protein-level changes after mimic transfection. Interpreted by authors: that miR-34a "modulates" cyclin D1, c-myc, c-Met, Ki-67 and the Bcl-2 family directly. BGPT critical inference: no luciferase 3'UTR reporter, no seed-mutant rescue, and no antagomir-reversal experiment were performed in this paper, so direct targeting of any listed protein is not demonstrated here — changes could be secondary to G1 arrest or transfection stress. The authors themselves acknowledge miRNA targeting is context-dependent and that miRNA oligonucleotide therapy "needs additional studies" MicroRNA-34a Suppresses Cell Proliferation and Induces Apoptosis in U87 Glioma Stem Cells [2012].

Cross-Cancer Convergence (Supports Plausibility)

The direction of effects matches independent miR-34a studies in other tumor stem-cell compartments: in pancreatic cancer tumor-initiating cells, miR-34 restoration inhibited growth, induced apoptosis and G1 arrest while modulating Bcl-2 and Notch1/2 MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells [2009], and in prostate cancer stem cells miR-34a directly repressed CD44 to inhibit clonogenic expansion and metastasis The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 [2011]. In HCT116 colon cancer cells, miR-34a overexpression (7.46±1.36-fold) reduced Bcl-2 (P=0.002), increased Bax (P=0.010) and cut invasion to 62.76±8.44% of controls — the same Bcl-2↓/Bax↑ axis reported here Influence of microRNA-34a on proliferation, invasion and metastasis of HCT116 cells [2016]. This convergence raises confidence in the general tumor-suppressive biology of miR-34a, though none of these validate the specific targets claimed in U87 GSCs.

Blind Spots and Counterpoints

• Single cell line, in vitro only: findings derive entirely from one laboratory-adapted U87 culture (obtained from the Chinese Academy of Sciences Cell Bank); no patient-derived GSCs, no orthotopic/xenograft data, no tumor microenvironment.
• Supraphysiological dosing: mimics drove miR-34a ~8.36-fold above the GSC baseline (~2.3-fold above even parental U87 levels); phenotype could be an overexpression artifact not recapitulated by physiological p53-driven restoration.
• No rescue control: a miR-34a antagomir or inhibitor co-transfection would establish specificity; only scrambled oligos were used.
• GSC identity asserted, not quantified: CD133 sorting plus one-week sphere growth was used, but no limiting-dilution self-renewal frequency or serial-passage data establish stemness enrichment.
• Statistical transparency: three replicates per experiment, but only significance thresholds and "x ± sd" without per-figure n are given, limiting reanalysis.
• Record integrity: the extracted author list is partially garbled (duplicated/misjoined names), and 7 years of subsequent U87-GSC literature has moved toward patient-derived models, so this paper's citation impact is likely modest; treating it as an early confirmatory data point rather than a pillar is appropriate.

What would change this assessment: reproduction in multiple patient-derived GSC cultures at physiological miR-34a levels with antagomir rescue and direct 3'UTR target validation, or, conversely, failure of miR-34a restoration in such systems.

Author Reviews

Author names in the source record are partially garbled; the clearest full names are linked below.

 BGPT Paper Review

Study Novelty

Extends an already-established finding (miR-34a tumor suppression in 0308/1228 glioma stem cells, cited within the paper itself) to CD133-positive U87-derived GSCs; the conceptual frame and assays were standard for 2012.

Scientific Quality

Standard methods with triplicate experiments, but no direct target validation, no antagomir rescue, no in vivo data, single cell line, supraphysiological mimic dosing, only threshold P-values, and no cell-line authentication.

Study Generality

Findings are restricted to one laboratory-adapted cell line and one CD133-sorting scheme; mechanistic breadth is limited to a candidate protein list without target-level proof.

Study Usefulness

Useful as preclinical, hypothesis-generating support for miRNA replacement in glioma stem cells and as a cross-cancer confirmation of miR-34a tumor-suppressive biology.

Study Reproducibility

Oligo sequences, antibody dilutions, culture conditions and instruments are specified, aiding replication, but exact per-figure n, statistics, and validation data are under-reported.

Explanatory Depth

Describes correlated protein-level changes but lacks luciferase 3'UTR assays, seed-mutant controls or rescue experiments, so the claimed mechanistic causality remains indirect.